PhRMA Elects New Members of Board of Directors
Bayer Healthcare, Bristol-Myers Squibb, Sucampo Pharmaceuticals, Takeda Pharmaceuticals, and Horizon Pharma representatives join PhRMA board.
The Pharmaceutical Research and Manufacturers of America (PhRMA) announced the election of five of its newest members to its Board of Directors on June 16.
“Over the past couple of months, we have been pleased to welcome five exceptional leaders to PhRMA’s Board,” said John J. Castellani, PhRMA president and chief executive officer in a statement. “Our organization will benefit not only from their deep understanding of the economic, regulatory and legislative issues facing our industry, but also from the global perspective, tested leadership and proven industry success they will bring to bear to help guide PhRMA’s work in the coming years.”
PhRMA’s newest board members include:â¨Werner Baumann, Chairman of the Board of Management, Bayer HealthCare AG; Giovanni Caforio, M.D., Chief Executive Officer, Bristol-Myers Squibb Company; Peter Greenleaf, Chief Executive Officer, Sucampo Pharmaceuticals, Inc.; Ramona Sequeira, President, Takeda Pharmaceuticals U.S.A., Inc.; and Timothy P. Walbert, Chairman, President & Chief Executive Officer, Horizon Pharma plc
Source: Pharmaceutical Research and Manufacturers of America (PhRMA)
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
